biomarker_id	biomarker	assessed_biomarker_entity	assessed_biomarker_entity_id	assessed_entity_type	condition	condition_id	exposure_agent	exposure_agent_id	best_biomarker_role	specimen	specimen_id	loinc_code	evidence_source	evidence	tag	vocab_pattern	biomarker_controlled_vocab	component_group	flags
BD0291-1	increased level of K18-M65	Keratin, type I cytoskeletal 18	UPKB:P05783	peptide	alcohol-associated liver disease	DOID:0070658			diagnostic	serum	UBERON:0001977		PubMed:37060262	High levels of K18-M65 characterized AUD patients with early ALD while levels in the minimal ALD group were similar to those in healthy controls. Serum K18-M65 can be used as a biomarker to detect early ALD stages with an excellent predictive value.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen		increased level of K18-M65 [biomarker_term_in_review]	203439	not_mapped;check_entity_type
BD0291-1	increased level of K18-M65	Keratin, type I cytoskeletal 18	UPKB:P05783	peptide	alcohol-associated liver disease	DOID:0070658			diagnostic	serum	UBERON:0001977		PubMed:33156105	Total (K18-M65) and caspase-cleaved K18 (K18-M30) were quantified in pretreatment sera... K18 fragments were markedly elevated in severe AH and strongly predicted steatohepatitis (alcoholic steatohepatitis)... In a large cohort of patients with severe AH, serum K18 strongly correlated with histological severity, independently associated with 90-day mortality, and predicted response to prednisolone therapy. Quantification of serum K18 levels could assist in clinical decision-making.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen		increased level of K18-M65 [biomarker_term_in_review]	203439	not_mapped;check_entity_type